Xite Holdings Ltd
Privately owned lottery
Unique alphabet-based lottery concept with a pending patent
Exclusive rights of the Alphabet Lottery IP allow the Company to license rights of use or commercial exploitation to any other approved company
Strategic partnership announced with SCCG Management for Global distribution
Unique lottery product for global audience
Xite’s signature product, the AZ Billions Lottery™, is a unique alphabet-based lottery concept with a pending patent. They believe this is the first new lottery concept to be launched into the world Lottery market since Powerball in the early 1990’s.
As owners of Alphabet Lottery IP Xite can license rights of use or commercial exploitation to any other company or person approved by the Company. Licences drive brand awareness and increase overall revenues, reducing risk in an array of formats, images, and types, each with the potential to set the odds for that game.
A scalable business where other products (including scratch card lottery, online, real money mainstream lotteries and social gaming) can be added to the product mix to complement the business, under the same gaming license.
All licences & corporate structures are in place
Much of the challenging work is complete with the creation of the AZ Billions Lottery™, the establishment of their licensed subsidiary (AZB Games NV in Curacao that holds the gaming licence in the Netherlands Antilles) along with a subsidiary in Cyprus, providing merchant facilities in Europe, are complete and ready for a launch.
Funds will be used to finance the launch of the business by strengthening the marketing, IT, operations, and other corporate services on the journey to profitability and beyond.
ResolutionRx Ltd was formed in Australia in January 2023 by RespireRx as an unlisted public company. RespireRx Pharmaceuticals Inc. (US OTC: RSPI) is in the process of contributing, via sublicense and license with ResolutionRx, its cannabinoid drug development program subject to certain liabilities.
ResolutionRx is engaging in the R&D associated with that program, initially for the development of a new formulation of dronabinol for use in Phase 3 clinical trial and the filing of regulatory approval for the treatment of obstructive sleep apnoea (“OSA”).
The current total budget for that program over the next several years is approximately A$24.8M, most, but not all of which is expected to be eligible for the R&D tax refund expected to be 43.5%.
The offer aims to raise up to A$5M with the issuance of up to 500,000 shares at an offer price of A$10 per share.
This offer is only available to those that qualify as sophisticated investors under s708 Corporations Act 2001 investors.
Minimum individual investment of A$25,000
The pre-money valuation of approximately A$55M
Use of funds
Enter your text here...
Want to learn more?
Fill in the expression of interest form below